ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

More »
Stock Quote
Change (%) Stock is Up 0.09 (2.58%)
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
11/07/18ChromaDex Corporation Reports Third Quarter 2018 Financial Results
- Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million - Third Quarter 2018 Highlights vs. Third Quarter 2017 Net sales up 33%, fueled by growth of TRU NIAGEN®, which increased by 97%; TRU NIAGEN sales at 84% of NIAGEN-related sales, up from 60% Gross profit as a percentage of net sales improved by 580 basis points to 53.7%; Launched TRU NIAGEN PRO (60ct, 300mg per capsule), the highest dose of NR in a single capsule; Earned certification from NSF International Ce... 
Printer Friendly Version
11/06/18ChromaDex Appoints Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation
LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective immediately. Roberts brings over 30 years of experience in scientific innovation and product development, launching hundreds of products while building global R&D teams. He joins the Company most recently from Pharmavite, a consumer-packaged goods Company which manufactures the Na... 
Printer Friendly Version
10/31/18ChromaDex to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
LOS ANGELES, Oct. 31, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., Nov. 7, 2018 at 4:30 p.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2018. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to di... 
Printer Friendly Version
What's New
Q3 2018 Earnings Presentation PDF
2018 Q3 Quarterly Report on Form 10Q PDF
September 2018 Investor Presentation PDF
July 2018 Investor Presentation PDF
2018 Proxy Statement  PDF
2017 Annual Report on Form 10-K PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.